A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Affiliation
Yale University School of Medicine, Department of Psychiatry, Substance Abuse Treatment Unit, 1 Long Wharf, New Haven, CT 06419, United States. cfarren@stpatsmail.comIssue Date
2009-01-01MeSH
AdultAge of Onset
Alcoholism
Cognitive Therapy
Combined Modality Therapy
Double-Blind Method
Drug Therapy, Combination
Ethnic Groups
Female
Humans
Male
Marital Status
Middle Aged
Naltrexone
Narcotic Antagonists
Patient Compliance
Patient Selection
Psychiatric Status Rating Scales
Psychotherapy
Serotonin Uptake Inhibitors
Sertraline
Treatment Outcome
Metadata
Show full item recordCitation
A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence. 2009, 99 (1-3):317-21 Drug Alcohol DependJournal
Drug and alcohol dependenceDOI
10.1016/j.drugalcdep.2008.06.006PubMed ID
18644685Additional Links
doi:10.1016/j.drugalcdep.2008.06.006Abstract
Significant preclinical evidence exists for a synergistic interaction between the opioid and the serotonin systems in determining alcohol consumption. Naltrexone, an opiate receptor antagonist, is approved for the treatment of alcohol dependence. This double-blind placebo-controlled study examined whether the efficacy of naltrexone would be augmented by concurrent treatment with sertraline, a selective serotonin receptor uptake inhibitor (SSRI).One hundred and thirteen participants meeting DSM IV alcohol dependence criteria, who were abstinent from alcohol between 5 and 30 days, were randomly assigned to receive one of two treatments at two sites. One group received naltrexone 12.5 mg once daily for 3 days, 25 mg once daily for 4 days, and 50 mg once daily for the next 11 weeks, together with placebo sertraline. The other group received naltrexone as outlined and simultaneously received sertraline 50 mg once daily for 2 weeks, followed by 100 mg once daily for 10 weeks. Both groups received group relapse prevention psychotherapy on a weekly basis.
Compliance and attendance rates were comparable and high. The groups did not differ on the two primary outcomes, time to first drink and time to relapse to heavy drinking, or on secondary treatment outcomes. With the exception of sexual side effects which were more common in the combination group, most adverse events were similar for the two conditions.
As the doses are tested in combination with specialized behavioral therapy, this study does not provide sufficient evidence for the combined use of sertraline and naltrexone above naltrexone alone.
Item Type
ArticleLanguage
enISSN
1879-0046ae974a485f413a2113503eed53cd6c53
10.1016/j.drugalcdep.2008.06.006
Scopus Count
Collections
Related articles
- A Systematic Review of Naltrexone for Attenuating Alcohol Consumption in Women with Alcohol Use Disorders.
- Authors: Canidate SS, Carnaby GD, Cook CL, Cook RL
- Issue date: 2017 Mar
- Family intervention therapy in alcohol dependence syndrome: One-year follow-up study.
- Authors: Suresh Kumar PN, Thomas B
- Issue date: 2007 Jul
- Naltrexone.
- Issue date: 2012